A new Intermountain Health study finds that peripheral artery disease, a condition that affects more than 10 million Americans over the age of 40, is often underdiagnosed and undertreated, with fewer ...

Advances in PCI over the past decade mean the procedure can now approximate results only previously achieved with open-heart bypass surgery, new data show.

STRIDE investigator Marc Bonaca, MD, MPH, University of Colorado School of Medicine, highlights how the data could provide insight into peripheral artery disease and type 2 diabetes treatment options.

A new Intermountain Health study finds that peripheral artery disease, a condition that affects more than 10 million Americans over the age of 40, is often underdiagnosed and undertreated, with fewer ...

A new Intermountain Health study finds that peripheral artery disease, a condition that affects more than 10 million ...

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...

The GLP-1 agonist has shown convincing benefits in yet another population, patients with peripheral arterial disease, in a ...

CHICAGO -- Semaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time building ...

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with symptomatic peripheral artery ...

Novo Nordisk (NVO) says its obesity drug Ozempic improved walking distance for diabetes patients with peripheral artery ...

The treatment of many patients with peripheral artery disease is not optimal, and indeed is much worse than that in patients ...